Key Insights

Highlights

Treatment Research

4 treatments under study, led by Ad Shr Active Lt And Extendedrelease Melatonin 2mg

Clinical Risk Assessment

Based on trial outcomes

Moderate Risk

Score: 30/100

Termination Rate

0.0%

0 terminated out of 1 trials

Late-Stage Pipeline

100%

1 trials in Phase 3/4

Results Transparency

0%

0 of 0 completed with results

Key Signals

Data Visualizations

Phase Distribution

1Total
Phase 3 (1)

Trial Status

Recruiting1

Clinical Trials (1)

Showing 1 of 1 trials
NCT07120880Phase 3RecruitingPrimary

Efficacy of Chronotherapeutic Combination for Major Depressive Episode With Insomnia

Showing all 1 trials

Research Network

Common Treatments

  • Ad Shr Active Lt And Extendedrelease Melatonin 2mg1
  • Ad Shr Placebo Lt And Placebo Melatonin1
  • Ad Shr Active Lt And Placebo Melatonin1
  • Ad Shr Placebo Lt And Extendedrelease Melatonin 2mg1

Active Sponsors

  • Assistance Publique Hopitaux De Paris1
  • Assistance Publique - Hôpitaux de Paris1

Top Investigators

Related Conditions

  • Depressive Episode1
  • Insomnia1

Activity Timeline